FORA Capital’s Corcept Therapeutics CORT Stock Holding History

FORA Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-4,320	Closed	-$73K	–	704
2020 Q2	$73K	Buy	+4,320	New	+$60.7K	0.03%	569

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FORA Capital's CORT Position: Q3 2020 in Review

FORA Capital sold out of Corcept Therapeutics (CORT) in Q3 2020, closing a stake of 4,320 shares — an estimated $73K sold.

FORA Capital first reported a position in CORT in Q2 2020 and held it in 1 quarter. The position peaked at $73K in Q2 2020. 223 funds tracked by Wall St. Rank hold CORT as of Q3 2020.

FORA Capital reported no remaining Corcept Therapeutics position as of Q3 2020 after selling out during the quarter.
FORA Capital sold 4,320 Corcept Therapeutics shares in Q3 2020, an estimated $73K.
FORA Capital first reported a position in Corcept Therapeutics in Q2 2020 and held it in 1 quarter.
FORA Capital's Corcept Therapeutics position peaked at $73K in Q2 2020.
223 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2020.

Based on FORA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.